Techalt Inc's Stan's Rodeo Ointment Goes for the Olympic Gold and Then Plans to Enter into Billion Dollar over the Counter Market.
SEATTLE -- Techalt, Inc. (Pink Sheets: TCLT TCLT Tentative Calculated Landing Time ) ("Techalt" or "Company") announced SRO See Self-regulatory organization.
See self-regulatory organization (SRO). will be dispensed at the 2008 Beijing Olympic Games. Stanley Johnston, SRO inventor and former Major League Baseball "MLB" and "Major Leagues" redirect here. For other uses, see MLB (disambiguation) and Major Leagues (disambiguation).
Major League Baseball (MLB) is the highest level of play in North American professional baseball. trainer with 23 years experience stated, "In my experience, when a player had the option of choosing an ointment on the shelf in the training room, they would always choose SRO. The Neosporin and Triple Antibiotic Ointment would be still on the shelf virtually unused at the end of the season."
Stanley Johnston reports that Major Baseball League players have claimed that SRO not only protects the area from infection, but also would provide pain relief from dermal dermal /der·mal/ (der´mal) pertaining to the dermis or to the skin.
der·mal or der·mic
Of or relating to the skin or dermis. injury. Dan Gribbon, an above-knee amputee am·pu·tee
A person who has had one or more limbs removed by amputation. (who now utilizes a prosthetic pros·thet·ic
1. Serving as or relating to a prosthesis.
2. Of or relating to prosthetics.
serving as a substitute; pertaining to prostheses or to prosthetics. leg) stated "SRO is the only topical ointment that not only heals the sores I get from my prosthesis prosthesis (prŏs`thĭsĭs): see artificial limb.
Artificial substitute for a missing part of the body, usually an arm or leg. faster but the pain is diminished."
An independent market analyst projects SRO's Over The Counter (OTC OTC
See over-the-counter market (OTC). ) opportunity, to be as much as $150 million per year, with additional market growth expected. The Over The Counter process, depending what the FDA FDA
Food and Drug Administration
n.pr See Food and Drug Administration.
n.pr the abbreviation for the Food and Drug Administration. will require, would likely take 18 to 36 months to complete. The Company plans increased marketing to expand its prescription market base so upon completion of OTC approval, SRO could experience rapid increase in market share.
SRO's category is Neosporin, Triple Antibiotic Ointment and other topical ointments. Despite lacking scientific testing, testimony of athletes and consumers suggests SRO provides the same barrier of protection as other topical ointments, but its unique formula the users claim more rapid pain relief and faster healing of dermal wounds.
Techalt is in process of securing financing for (i) expanding SRO's distribution channels and marketing efforts and (ii) completing the process for obtaining an over the counter designation from the United States Food and Drug Administration United States Food and Drug Administration (FDA),
n.pr a unit of the Public Health Service created to protect the health of the nation against impure and unsafe foods, drugs, and cosmetics. .
About Stan's Rodeo Ointment ("SRO"):
SRO is a sports cream product designed to accelerate the healing time for abrasions, lacerations, blisters and other open wounds to the skin, while diminishing the pain. Developed by Stanley Johnston, former head athletic trainer for the Los Angeles Dodgers "Dodgers" and "Brooklyn Dodgers" redirect here. For the American football team, see Brooklyn Dodgers (football). For the Eastern Basketball Association team, see Brooklyn Dodgers (basketball). , SRO is currently available by prescription and used by prominent Olympic and professional athletes. Techalt also acquired the rights to develop Stan's Blister Rub ("SBR SBR - Spectral Band Replication "), which is a combination of materials that strengthen the skin after it has healed to reduce the likelihood of the reoccurrence of blisters to the applied area. Patent protection has been filed covering the formulations and processing of SRO with the US Patent and Trademark Office. The Company anticipates that a patent will be issued sometime in 2008.
Techalt is a public holding company dedicated to pursuing acquisition, licensing and financing opportunities with start-up and mid-stage companies. Techalt focuses on companies with innovative or alternative technologies, particularly in the software, communications, environmental and health and wellness sectors.
Media and Investor Relations: www.EquityDigest.com
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended ("the Exchange Act"), as such, may involve risks and uncertainties. Forward-looking statements are based upon certain assumptions and describe future plans, strategies and expectations, are generally identifiable by the use of words as "believe," "expect," "intend," "anticipate," "project," or other similar expressions. Forward-looking statements relate to, among other things, future performance, and perceived opportunities in the market and statements regarding the Company's mission and vision. The Company's actual results, performance and achievements may differ materially from the results, performance, and achievements expressed or implied in such forward-looking statements. Additional factors could materially affect these forward-looking statements and/or predictions include, among other things: (1) managing acquisitions and expansion of operations; (2) obtaining necessary financing and managing existing debt; (3) completing the investigation, acquisition and integration of new business opportunities; (4) complying with federal, state and local government and international regulations; and (5) other factors over which we have little or no control.